Avanir Pharmaceuticals Announces Completion of Patient Enrollment in PRIME
ALISO VIEJO, Calif., July 1, 2013
ALISO VIEJO, Calif., July 1, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc.
(NASDAQ: AVNR) today announced completion of patient enrollment in the
company's phase II, placebo controlled study testing three doses of AVP-923
for the treatment of central neuropathic pain in multiple sclerosis. Top-line
results from this study are expected in the fourth calendar quarter of 2013.
"Final completion of enrollment in PRIME is an important milestone in the
AVP-923 development pathway," said Joao Siffert, MD, chief scientific officer
at Avanir. "We are looking forward to the results from this study to help
guide design of our phase III studies in neuropathic pain."
About the PRIME Study
The objectives of the PRIME (Pain Research In Multiple sclErosis) study are to
evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment
of central neuropathic pain in patients with multiple sclerosis. The trial is
a multicenter, randomized, double-blind, placebo-controlled, 4-arm parallel
group study. Eligible patients receive one of three dose levels of AVP-923
containing either 45mg DM/10 mg Q, 30mg DM/10mg Q, 20mg DM/10mg Q or placebo,
daily for 12 weeks. The primary efficacy endpoint will be measured based on
the Numeric Pain Rating Scale (PRS) as recorded in patient diaries. Primary
analysis of this endpoint will correlate pain scores with dextromethorphan
plasma concentrations. Secondary analysis will correlate pain scores with
AVP-923 dose and also compare pain scores for those treated with placebo
versus drug in each dose group. Secondary assessments include measures of
fatigue, impact of MS on daily life, sleep quality, spasticity, cognition and
depression. Standard safety assessments were also conducted.
AVP-923 is a combination of two well-characterized compounds, the active CNS
ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor
antagonist and sigma-1 receptor agonist) plus low-dose quinidine sulfate (a
CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of
dextromethorphan. AVP-923 is being studied in several ongoing company
sponsored Phase II clinical trials including agitation in Alzheimer's disease,
neuropathic pain in Multiple Sclerosis, levodopa-induced dyskinesia in
Parkinson's disease, and an investigator initiated study of behavioral
symptoms of autism in adults. AVP-923 is an investigational drug not approved
by the FDA.
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on
bringing innovative medicines to patients with central nervous system
disorders of high unmet medical need. As part of our commitment, we have
extensively invested in our pipeline and are dedicated to advancing medicines
that can substantially improve the lives of patients and their loved ones. For
more information about Avanir, please visit www.avanir.com.
AVANIR^® is a trademark or registered trademark of Avanir Pharmaceuticals,
Inc. in the United States and other countries.
^©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.
Forward Looking Statements
Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding Avanir's plans,
potential opportunities, financial or other expectations, projections, goals
objectives, milestones, strategies, market growth, timelines, legal matters,
product pipeline, clinical studies, product development and the potential
benefits of its commercialized products and products under development are
forward-looking statements within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including the risks and uncertainties associated
with, the market demand for and acceptance of Avanir's products domestically
and internationally, research, development and commercialization of new
products domestically and internationally, including the risks and
uncertainties associated with meeting the objectives of the study of AVP-786,
and AVP-923, including, but not limited to, risks relating to the successful
development of these investigational drugs, delays or failures in enrollment,
or delays in the release of study results, obtaining additional indications
for commercially marketed products domestically and internationally, obtaining
and maintaining regulatory approvals domestically and internationally, and
other risks detailed from time to time in the Company's most recent Annual
Report on Form 10-K and other documents subsequently filed with or furnished
to the Securities and Exchange Commission. These forward-looking statements
are based on current information that may change and you are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date of this press release. All forward-looking statements are
qualified in their entirety by this cautionary statement, and the Company
undertakes no obligation to revise or update any forward-looking statement to
reflect events or circumstances after the issuance of this press release.
Avanir Investor & Media Contact
Ian Clements, PhD
+1 (949) 389-6700
SOURCE Avanir Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.